Summary
In this project our aim is to validate a small scale absorption model for sustainable and animal-free screening of pharmaceutical formulations intended for oral use. The model will use small volumes and low quantities of drugs and excipients, contributing to the sustainable approach taken. The advanced model will enable companies to early on identify the best formulation which enable and increase absorption after oral intake. The model can replace animal models, directing the research to few proof-of-concept studies in vivo in higher preclinical species rather than making use of formulation screens in rodents and higher species. Hence, our technology is a game-changer in the drug development process and significantly contributing to the reduce and replace focus areas of the 3R principles. The company has a strong scientific foundation, and the key people of Enphasys AB have extensive network with leading pharma and biotech companies as well as scientific key opinion leaders. Currently the company has validated its business with regard to our services to customers making use of prime examples from big pharma. In this Women Tech EU project, our aims are to explore a new small scale innovation building on the knowledge acquired on the patented technology own by Enphasys AB. Here, we will analyse the market value, extend and validate our business plan including the new small scale innovation, analyse the IP landscape for the new innovation, and identify sustainable manufacturer(s), preferably located in Europe.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101071626 |
| Start date: | 01-06-2022 |
| End date: | 31-05-2023 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
In this project our aim is to validate a small scale absorption model for sustainable and animal-free screening of pharmaceutical formulations intended for oral use. The model will use small volumes and low quantities of drugs and excipients, contributing to the sustainable approach taken. The advanced model will enable companies to early on identify the best formulation which enable and increase absorption after oral intake. The model can replace animal models, directing the research to few proof-of-concept studies in vivo in higher preclinical species rather than making use of formulation screens in rodents and higher species. Hence, our technology is a game-changer in the drug development process and significantly contributing to the reduce and replace focus areas of the 3R principles. The company has a strong scientific foundation, and the key people of Enphasys AB have extensive network with leading pharma and biotech companies as well as scientific key opinion leaders. Currently the company has validated its business with regard to our services to customers making use of prime examples from big pharma. In this Women Tech EU project, our aims are to explore a new small scale innovation building on the knowledge acquired on the patented technology own by Enphasys AB. Here, we will analyse the market value, extend and validate our business plan including the new small scale innovation, analyse the IP landscape for the new innovation, and identify sustainable manufacturer(s), preferably located in Europe.Status
SIGNEDCall topic
HORIZON-EIE-2021-SCALEUP-01-03Update Date
09-02-2023
Images
No images available.
Geographical location(s)
